Agios Pharmaceuticals

MA - CambridgePharmaceutical4 H-1B visas (FY2023)

Focus: Agios Pharmaceuticals is a Cambridge-based small-molecule biotech founded in 2008, focused on rare blood disorders and oncology with a single peak-revenue product (PYRUKYND/mitapivat). The company generates 100% of revenue from one indication, representing a highly concentrated commercial footprint.

Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Open Jobs

About Agios Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Agios Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from Agios Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

PYRUKYND

Pyruvate Kinase Deficiency

$4M Part D

Peak

Help build intelligence for Agios Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Magnetic Resonance Imaging

Prostate Cancer

N/A

Clinical Trials (1)

NCT05384002An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum

N/A

Prostate Cancer AI Platform Study

Prostate Cancer

N/A

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

Pyruvate Kinase Deficiency

N/A

Clinical Trials (1)

NCT04964323Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

N/A

Pyruvate Kinase Deficiency Natural History Study

Pyruvate Kinase Deficiency

N/A

Clinical Trials (1)

NCT02053480Pyruvate Kinase Deficiency Natural History Study

N/A

Blood Draw

Pyruvate Kinase Deficiency

N/A

Clinical Trials (1)

NCT04902833Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

N/A

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Advanced Solid Tumors

N/A

Clinical Trials (1)

NCT03361358Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

N/A

Pyruvate Kinase Deficiency Global Longitudinal Registry

Pyruvate Kinase Deficiency

N/A

Clinical Trials (2)

NCT03481738Pyruvate Kinase Deficiency Global Longitudinal Registry

N/A

NCT04995315Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008

MTAP Loss Pre-Screening Study

Advanced Solid Tumors

N/A

AG-348

Sickle Cell Disease

Phase 1

Clinical Trials (5)

NCT03853798Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Phase 3

NCT05031780A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

AG-348

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03703505A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Phase 1

AG881 Formulation 1

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04128787A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

Phase 1

AG-946

Healthy Volunteers

Phase 1

Clinical Trials (2)

NCT05490446A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Phase 2

NCT04536792A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

[14C]-AG-120

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02489513Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

Phase 1

AG-348

Healthy

Phase 1

Clinical Trials (1)

NCT03250598Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Phase 1

AG221

Healthy Volunteers

Phase 1

AG-881

Healthy Male Participants

Phase 1

Clinical Trials (1)

NCT03960502A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Phase 1

AG-348 Sequence A

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03397329Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Phase 1

AG-348

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT02149966A Phase I Study of AG-348 in Healthy Volunteers

Phase 1

AG120

Healthy

Phase 1

Clinical Trials (1)

NCT02579707Food Effect Study of AG120 in Healthy Subjects

Phase 1

AG120

Healthy

Phase 1

Clinical Trials (1)

NCT02831972Drug-Drug Interaction Study of AG120 in Healthy Subjects

Phase 1

AG881

Acute Myeloid Leukemia (AML)

Phase 1

Clinical Trials (1)

NCT02492737Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Phase 1

enasidenib

Acute Myeloid Leukemia

Phase 1

AG881

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04145128A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants

Phase 1

AG-181

Phenylketonuria

Phase 1

Clinical Trials (1)

NCT07241234A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria

Phase 1

vorasidenib

Acute Myeloid Leukemia

Phase 1

AG-236

Anemia

Phase 1

Clinical Trials (2)

NCT07859423A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera

Phase 2/3

NCT07075640A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

AG-519

Anemia

Phase 1

Clinical Trials (1)

NCT02630927A Safety and Tolerability Study of AG-519 in Healthy Subjects

Phase 1

AG-636

Lymphoma

Phase 1

Clinical Trials (1)

NCT03834584A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Phase 1

AG-881

Healthy Participants

Phase 1

Clinical Trials (1)

NCT04015687A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults

Phase 1

AG-348

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT02108106A Phase I Study of AG-348 in Healthy Volunteers

Phase 1

AG-120

Chondrosarcoma

Phase 2

Clinical Trials (1)

NCT04278781AG-120 in People With IDH1 Mutant Chondrosarcoma

Phase 2

AG-348

Pyruvate Kinase Deficiency

Phase 2

Clinical Trials (1)

NCT02476916A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

Phase 2

tebapivat

Sickle Cell Disease

Phase 2

Clinical Trials (1)

NCT06745271A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

Phase 1

AG-348

Thalassemia

Phase 2

Clinical Trials (1)

NCT03692052A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Phase 2

ivosidenib

Acute Myeloid Leukemia

Phase 2

Clinical Trials (4)

NCT03282513A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Phase 1

NCT03564821IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Placebo

Pyruvate Kinase Deficiency

Phase 3

Clinical Trials (5)

NCT05175105A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

Phase 3

NCT03548220A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

AG-348

Pyruvate Kinase Deficiency

Phase 3

Clinical Trials (1)

NCT03559699A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Phase 3

mitapivat

Pyruvate Kinase Deficiency

Phase 4

Clinical Trials (5)

NCT05777993A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

Phase 4

NCT06286046A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Agios Pharmaceuticals

About Agios Pharmaceuticals

Key Products

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship